A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder

Journal of Clinical Psychopharmacology

Volumn 31, Issue 5, 2011, Pages 643-646

  Robinson, Donald S ^a   Kajdasz, Daniel K ^b   Gallipoli, Susan ^b   Whalen, Heidi ^b   Wamil, Art ^b,c   Reed, Carol R ^b  

^a Worldwide Drug Development   (United States)

^b Trovis Pharmaceuticals LLC   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

long term safety; major depressive disorder; sexual function; Vilazodone

Indexed keywords

PLACEBO; VILAZODONE;

ABNORMAL DREAMING; ADULT; AGED; ANORGASMIA; ANXIETY; ARTICLE; AUTOMUTILATION; BACKACHE; CHANGES IN SEXUAL FUNCTIONING QUESTIONNAIRE; CLINICAL CHEMISTRY; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIARRHEA; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EJACULATION DISORDER; ELECTROCARDIOGRAM; ERECTILE DYSFUNCTION; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HAMILTON SCALE; HUMAN; INCREASED APPETITE; INSOMNIA; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; NAUSEA; PHYSICAL EXAMINATION; PNEUMONIA; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RHINOPHARYNGITIS; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE ATTEMPT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ADULT; ANTIDEPRESSIVE AGENTS; BENZOFURANS; DEPRESSIVE DISORDER, MAJOR; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDOLES; MALE; MIDDLE AGED; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 80052434651     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31822c6741     Document Type: Article

References (14)

1. Hughes ZA, Starr KR, Langmead CJ, et al. Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone. Eur J Pharmacol. 2005;510:49-57. (Pubitemid 40312389)
2. Dawson LA, Watson JM. Vilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders. CNS Neurosci Ther. 2009;15:107-117.
3. Rickels K, Athanasiou M, Robinson DS, et al. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70:326-333.
4. Khan A, Cutler AJ, Kajdasz DK, et al. Efficacy and tolerability of vilazodone, a dual-acting serotonergic antidepressant, in the treatment of patients with major depressive disorder (MDD). Poster presented at the 163rd Annual Meeting of the American Psychiatric Association, May 22-26, 2010, New Orleans, LA.
5. Sheehan DV, Lecrubier Y, Harnett Sheehan K, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998; 59(suppl 20):22-33. (Pubitemid 29001829)
6. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
7. Clayton AH, McGarvey EL, Clavet GJ. The Changes in Sexual Functioning Questionnaire (CSFQ): development, reliability, and validity. Psychopharmacol Bull. 1997;33:731-745. (Pubitemid 28128129)
8. Keller A, McGarvey EL, Clayton AH. Reliability and construct validity of the Changes in Sexual Functioning Questionnaire short-form (CSFQ-14). J Sex Marital Ther. 2006;32:43-52.
9. Montgomery SA, A? sberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389. (Pubitemid 9136500)
10. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised 1976. Rockville, MD: National Institute of Mental Health, US Dept of Health, Education, and Welfare; 1976;218-222.
11. Clayton AH, McGarvey EL, Clavet GJ, et al. Comparison of sexual functioning in clinical and nonclinical populations using the Changes in Sexual Functioning Questionnaire (CSFQ). Psychopharmacol Bull. 1997;33:747-753. (Pubitemid 28128130)
12. Gelenberg AJ, Freeman MP, Markowitz JC, et al, for the Work Group on Major Depressive Disorder. American Psychiatric Association: Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition. 2010;167(10S). DOI: 10.1176/appi.books.9780890423387.654001. Available at: http://www.psychiatryonline.com/. Accessed January 8, 2011.
13. Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry. 2002;63:357-366. (Pubitemid 34456365)
14. Ferguson JM. SSRI antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin Psychiatry. 2001;3:22-27. (Pubitemid 33807486)